Introduction: According to the U.S Centres for Disease Control and Prevention, together the chronic diseases account for 63% of all deaths worldwide. The chief causes of these diseases are through the induction of inflammation that is by the changes in diet and lifestyle. Wide heterogeneous group of drugs called anti-inflammatories are used to suppress the innate inflammatory pathway and thus prevents persistent or recurrent inflammation. Objectives: To assess the benefits of anti-inflammatory drugs in chronic diseases, to evaluate the challenges that result in a poor therapeutic outcome, to assess the developing co-morbidities in patients on the anti-inflammatory drug(s) and to assess the betterment of patient concerning the pain-related quality of life. Materials and methods: A prospective observational study enrolled 100 patients. Antiinflammatory prescriptions were assessed, evaluated and questionnaire provided to patients is assessed for the benefits and challenges of the anti-inflammatories for 6 months. Results: In a sample of 100 patients, 41were men, 59 were women. According to the visual analogue scale, on admission, moderate pain was in 52% and severe pain in 46%. After treatment during discharge, 4% were with no pain, 8% moderate and 88% minor pain. This shows that the pain severity dropped in every patient during their discharge i.e., the benefit is attained. An average of 18.17% improvement due to anti-inflammatory use was established in the patient’s pain-related QOL. The factors like suspected ADR (11.61%), DDIs (36.61%), drug choice problems (11.61%), no tapering of dose (38.73%) and comorbidities (1.4%) were the major challenges for incomplete recovery. The co-morbidities identified – pneumonia (0.02%) oral candidiasis (0.01%) anaemia (0.01%). Conclusion: Though these anti-inflammatories are of great help in arresting inflammation and pain, their use must be tempered according to the need with the realization that they can cause potential harm.
